RU2707255C1 - Способ получения ботулотоксина - Google Patents
Способ получения ботулотоксина Download PDFInfo
- Publication number
- RU2707255C1 RU2707255C1 RU2018113925A RU2018113925A RU2707255C1 RU 2707255 C1 RU2707255 C1 RU 2707255C1 RU 2018113925 A RU2018113925 A RU 2018113925A RU 2018113925 A RU2018113925 A RU 2018113925A RU 2707255 C1 RU2707255 C1 RU 2707255C1
- Authority
- RU
- Russia
- Prior art keywords
- botulinum toxin
- exchange chromatography
- buffer
- anion exchange
- carried out
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title claims abstract description 193
- 229940053031 botulinum toxin Drugs 0.000 title claims abstract description 178
- 238000000034 method Methods 0.000 title claims abstract description 139
- 238000005571 anion exchange chromatography Methods 0.000 claims abstract description 91
- 239000000872 buffer Substances 0.000 claims abstract description 37
- 239000002244 precipitate Substances 0.000 claims abstract description 37
- 238000011140 membrane chromatography Methods 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims abstract description 20
- 239000002253 acid Substances 0.000 claims abstract description 15
- 102000016911 Deoxyribonucleases Human genes 0.000 claims abstract description 5
- 108010053770 Deoxyribonucleases Proteins 0.000 claims abstract description 5
- 102000006382 Ribonucleases Human genes 0.000 claims abstract description 5
- 108010083644 Ribonucleases Proteins 0.000 claims abstract description 5
- 230000003472 neutralizing effect Effects 0.000 claims abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 70
- 238000000746 purification Methods 0.000 claims description 59
- 238000001556 precipitation Methods 0.000 claims description 50
- 238000000108 ultra-filtration Methods 0.000 claims description 42
- 238000011118 depth filtration Methods 0.000 claims description 32
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 28
- 238000005277 cation exchange chromatography Methods 0.000 claims description 28
- 238000001914 filtration Methods 0.000 claims description 22
- 238000001471 micro-filtration Methods 0.000 claims description 22
- 238000011026 diafiltration Methods 0.000 claims description 18
- 239000012064 sodium phosphate buffer Substances 0.000 claims description 15
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 13
- 241000193155 Clostridium botulinum Species 0.000 claims description 12
- 239000011148 porous material Substances 0.000 claims description 11
- 238000004587 chromatography analysis Methods 0.000 claims description 10
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims description 9
- 238000011146 sterile filtration Methods 0.000 claims description 9
- 238000005352 clarification Methods 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000006386 neutralization reaction Methods 0.000 claims description 3
- 230000002572 peristaltic effect Effects 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 238000004448 titration Methods 0.000 claims description 3
- 101000963974 Hydrophis stokesii Alpha-elapitoxin-Ast2b Proteins 0.000 claims description 2
- 101000964025 Naja naja Long neurotoxin 3 Proteins 0.000 claims description 2
- 101000822778 Naja naja Long neurotoxin 4 Proteins 0.000 claims description 2
- 101000822797 Naja naja Long neurotoxin 5 Proteins 0.000 claims description 2
- 101710182223 Toxin B Proteins 0.000 claims description 2
- 239000012539 chromatography resin Substances 0.000 claims description 2
- 238000004440 column chromatography Methods 0.000 claims description 2
- 108010010958 snake venom neurotoxin F Proteins 0.000 claims description 2
- 238000010306 acid treatment Methods 0.000 claims 1
- 239000003957 anion exchange resin Substances 0.000 claims 1
- 238000000465 moulding Methods 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 238000005374 membrane filtration Methods 0.000 abstract 1
- 230000008569 process Effects 0.000 description 61
- 239000000243 solution Substances 0.000 description 36
- 239000003053 toxin Substances 0.000 description 31
- 108700012359 toxins Proteins 0.000 description 29
- 239000000523 sample Substances 0.000 description 28
- 231100000765 toxin Toxicity 0.000 description 27
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 26
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 26
- 235000011130 ammonium sulphate Nutrition 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- 239000012535 impurity Substances 0.000 description 19
- 239000011347 resin Substances 0.000 description 18
- 229920005989 resin Polymers 0.000 description 18
- 235000002639 sodium chloride Nutrition 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 13
- 208000024777 Prion disease Diseases 0.000 description 13
- 208000010544 human prion disease Diseases 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- 238000004140 cleaning Methods 0.000 description 12
- 101710154606 Hemagglutinin Proteins 0.000 description 11
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 11
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 11
- 101710176177 Protein A56 Proteins 0.000 description 11
- 238000007796 conventional method Methods 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 102000029797 Prion Human genes 0.000 description 10
- 108091000054 Prion Proteins 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 10
- 239000001488 sodium phosphate Substances 0.000 description 10
- 229910000162 sodium phosphate Inorganic materials 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 10
- 238000003916 acid precipitation Methods 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 239000000185 hemagglutinin Substances 0.000 description 9
- 238000000151 deposition Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 239000013076 target substance Substances 0.000 description 8
- 230000008021 deposition Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000002581 neurotoxin Substances 0.000 description 7
- 231100000618 neurotoxin Toxicity 0.000 description 7
- 231100000252 nontoxic Toxicity 0.000 description 7
- 230000003000 nontoxic effect Effects 0.000 description 7
- 239000012465 retentate Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 6
- 229940094657 botulinum toxin type a Drugs 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000013049 sediment Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 5
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 5
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- -1 DNA or RNA (see Chemical class 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000011218 seed culture Methods 0.000 description 4
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 3
- 102000008100 Human Serum Albumin Human genes 0.000 description 3
- 108091006905 Human Serum Albumin Proteins 0.000 description 3
- 101710138657 Neurotoxin Proteins 0.000 description 3
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 3
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 3
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000012149 elution buffer Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 231100000189 neurotoxic Toxicity 0.000 description 3
- 230000002887 neurotoxic effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- 241000193464 Clostridium sp. Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 2
- 108010005730 R-SNARE Proteins Proteins 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102000050389 Syntaxin Human genes 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 229940089093 botox Drugs 0.000 description 2
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 206010008129 cerebral palsy Diseases 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000028023 exocytosis Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000013028 medium composition Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 201000007770 spastic cerebral palsy Diseases 0.000 description 2
- 201000008417 spastic hemiplegia Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 208000000722 Akinetic Mutism Diseases 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 201000000251 Locked-in syndrome Diseases 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000005917 R-SNARE Proteins Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000002215 Synaptobrevin Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- LZCZIHQBSCVGRD-UHFFFAOYSA-N benzenecarboximidamide;hydron;chloride Chemical compound [Cl-].NC(=[NH2+])C1=CC=CC=C1 LZCZIHQBSCVGRD-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010364 biochemical engineering Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 150000001768 cations Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 229940098753 dysport Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000037957 feline spongiform encephalopathy Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000171 higher toxicity Toxicity 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000037427 ion transport Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940112646 myobloc Drugs 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011137 process chromatography Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000029219 regulation of pH Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000013017 sartobind Substances 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/147—Microfiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/58—Multistep processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/16—Diafiltration
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Water Supply & Treatment (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2015-0168196 | 2015-11-30 | ||
| KR1020150168196A KR101775682B1 (ko) | 2015-11-30 | 2015-11-30 | 보툴리눔 독소의 제조방법 |
| PCT/KR2016/013506 WO2017095062A1 (en) | 2015-11-30 | 2016-11-23 | Method for producing botulinum toxin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2707255C1 true RU2707255C1 (ru) | 2019-11-25 |
Family
ID=58797138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018113925A RU2707255C1 (ru) | 2015-11-30 | 2016-11-23 | Способ получения ботулотоксина |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10619143B2 (enExample) |
| EP (1) | EP3383889A4 (enExample) |
| JP (1) | JP6574528B2 (enExample) |
| KR (1) | KR101775682B1 (enExample) |
| CN (1) | CN108350043B (enExample) |
| AR (1) | AR107218A1 (enExample) |
| AU (2) | AU2016364597B2 (enExample) |
| BR (1) | BR112018007679A2 (enExample) |
| CA (1) | CA2997698C (enExample) |
| MX (1) | MX2018004650A (enExample) |
| RU (1) | RU2707255C1 (enExample) |
| TW (1) | TWI623549B (enExample) |
| WO (1) | WO2017095062A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
| JP5951490B2 (ja) * | 2009-10-21 | 2016-07-13 | ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 非複合ボツリヌス神経毒素を精製するための方法およびシステム |
| KR101723168B1 (ko) * | 2015-04-28 | 2017-04-05 | 주식회사 대웅 | 보툴리눔 독소의 제조를 위한 배지 조성물 |
| KR102463881B1 (ko) * | 2016-10-04 | 2022-11-07 | (주)메디톡스 | 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법 |
| KR102516203B1 (ko) * | 2019-04-15 | 2023-03-30 | (주)제테마 | 보툴리눔 독소의 제조방법 |
| KR102516204B1 (ko) * | 2019-04-15 | 2023-03-30 | (주)제테마 | 보툴리눔 독소의 정제방법 |
| EP3962924A1 (en) * | 2019-05-03 | 2022-03-09 | Genentech, Inc. | Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform |
| KR102287437B1 (ko) * | 2019-08-14 | 2021-08-09 | 주식회사 프로톡스 | 보툴리눔 독소의 제조방법 |
| TW202136286A (zh) * | 2019-12-20 | 2021-10-01 | 瑞士商葛德瑪控股公司 | 純化肉毒桿菌毒素的方法 |
| CN112480221A (zh) * | 2020-12-02 | 2021-03-12 | 湖北省农业科学院畜牧兽医研究所 | 产气荚膜梭菌毒素抗原浓缩工艺 |
| KR102724651B1 (ko) * | 2021-07-08 | 2024-11-01 | 주식회사 파마리서치바이오 | 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법 |
| CO2023018742A1 (es) * | 2023-12-29 | 2025-07-07 | Lifefactors S A S | Proceso de purificación de macromoléculas con etapas de precipitación selectiva, concentración y diálisis combinadas en condiciones constantes de estabilidad con el cual se obtienen formulaciones estables y de alta pureza |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015016462A1 (en) * | 2013-08-02 | 2015-02-05 | Daewoong Co., Ltd. | Method for production of botulinum toxin |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06192296A (ja) | 1992-10-28 | 1994-07-12 | Chiba Pref Gov | 治療用医薬品としての結晶ａ型ボツリヌス毒素の製造法。 |
| JPH06199296A (ja) | 1992-12-29 | 1994-07-19 | Toyota Motor Corp | ガスタービンエンジンを推進力とする水上飛行機 |
| DE19925739A1 (de) * | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| GB9914743D0 (en) * | 1999-06-24 | 1999-08-25 | Knoll Ag | Therapeutic agents |
| KR20030060150A (ko) * | 2002-01-07 | 2003-07-16 | (주)메디톡스 | 클로스트리디움 보툴리눔 ａ형 독소를 정제하는 방법 |
| US7452697B2 (en) * | 2003-09-25 | 2008-11-18 | Allergan, Inc. | Chromatographic method and system for purifying a botulinum toxin |
| CN1930186A (zh) * | 2005-03-03 | 2007-03-14 | 阿勒根公司 | 为获得梭菌毒素的梭菌细菌培养基及方法 |
| KR101025617B1 (ko) | 2008-02-25 | 2011-03-30 | 메덱스젠 주식회사 | 클로스트리디움 보툴리눔으로부터 보툴리눔 독소를정제하는 방법 |
| KR20090120222A (ko) * | 2008-05-19 | 2009-11-24 | (주)메디톡스 | 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법 |
| US8129139B2 (en) * | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
| JP2011074025A (ja) * | 2009-09-30 | 2011-04-14 | Chemo-Sero-Therapeutic Research Inst | ボツリヌス毒素の精製方法 |
| JP5951490B2 (ja) | 2009-10-21 | 2016-07-13 | ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 非複合ボツリヌス神経毒素を精製するための方法およびシステム |
| KR101134146B1 (ko) * | 2010-05-31 | 2012-04-19 | 메덱스젠 주식회사 | 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 |
| UY33452A (es) | 2010-06-16 | 2012-01-31 | Bayer Schering Pharma Ag | Triazolopiridinas sustituidas |
-
2015
- 2015-11-30 KR KR1020150168196A patent/KR101775682B1/ko active Active
-
2016
- 2016-11-23 WO PCT/KR2016/013506 patent/WO2017095062A1/en not_active Ceased
- 2016-11-23 JP JP2018540360A patent/JP6574528B2/ja active Active
- 2016-11-23 CA CA2997698A patent/CA2997698C/en active Active
- 2016-11-23 BR BR112018007679A patent/BR112018007679A2/pt active Search and Examination
- 2016-11-23 US US15/758,042 patent/US10619143B2/en active Active
- 2016-11-23 RU RU2018113925A patent/RU2707255C1/ru active
- 2016-11-23 CN CN201680061642.XA patent/CN108350043B/zh active Active
- 2016-11-23 AU AU2016364597A patent/AU2016364597B2/en active Active
- 2016-11-23 EP EP16870958.2A patent/EP3383889A4/en active Pending
- 2016-11-23 MX MX2018004650A patent/MX2018004650A/es unknown
- 2016-11-29 AR ARP160103642A patent/AR107218A1/es unknown
- 2016-11-30 TW TW105139480A patent/TWI623549B/zh active
-
2019
- 2019-02-26 AU AU2019201315A patent/AU2019201315B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015016462A1 (en) * | 2013-08-02 | 2015-02-05 | Daewoong Co., Ltd. | Method for production of botulinum toxin |
Non-Patent Citations (1)
| Title |
|---|
| АРТЕМЕНКО А. Р. и др. К вопросу об отсутствии взаимозаменяемости лекарственных препаратов ботулинического токсина типа А, Медицинский совет, 2015, N 5, C.112-123. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2997698C (en) | 2021-04-20 |
| AU2019201315B2 (en) | 2020-10-15 |
| TW201726703A (zh) | 2017-08-01 |
| CN108350043A (zh) | 2018-07-31 |
| TWI623549B (zh) | 2018-05-11 |
| AU2016364597B2 (en) | 2019-01-17 |
| MX2018004650A (es) | 2018-08-15 |
| BR112018007679A2 (pt) | 2018-11-06 |
| US10619143B2 (en) | 2020-04-14 |
| KR101775682B1 (ko) | 2017-09-06 |
| JP6574528B2 (ja) | 2019-09-11 |
| WO2017095062A1 (en) | 2017-06-08 |
| US20180251741A1 (en) | 2018-09-06 |
| AU2019201315A1 (en) | 2019-03-21 |
| CA2997698A1 (en) | 2017-06-08 |
| KR20170062694A (ko) | 2017-06-08 |
| AR107218A1 (es) | 2018-04-11 |
| AU2016364597A1 (en) | 2018-04-12 |
| EP3383889A1 (en) | 2018-10-10 |
| EP3383889A4 (en) | 2019-07-17 |
| CN108350043B (zh) | 2022-06-14 |
| JP2018533977A (ja) | 2018-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2707255C1 (ru) | Способ получения ботулотоксина | |
| KR101819129B1 (ko) | 비-복합체화된 보툴리눔 신경독소를 정제하기 위한 방법 및 시스템 | |
| KR102463881B1 (ko) | 보툴리눔 독소 함유 용액으로부터 보툴리눔 독소를 분리하는 방법 | |
| KR102516204B1 (ko) | 보툴리눔 독소의 정제방법 | |
| CA2559379A1 (en) | Process for producing human serum albumin by heating in presence of divalent cation | |
| US20220267368A1 (en) | Method for preparing botulinum toxin | |
| JP2024513914A (ja) | バイオコンジュゲート生産のためのプロセス | |
| JP2024501025A (ja) | 免疫グロブリンｇのプロセススケールでの単離のためのシステム及び方法 | |
| KR20200024896A (ko) | 용해 효소, 접선방향 유동 여과, 및 다중모드 크로마토그래피를 이용한, 백신 제조를 위한 다당류 정제 | |
| US20220081682A1 (en) | Botulinum toxin producing method | |
| TWI890364B (zh) | 使用多模式層析法純化肉毒毒素的改進方法 | |
| CN113121638B (zh) | 一种纯化重组蛋白的方法 | |
| TWI839783B (zh) | 提高純化收率的肉毒桿菌毒素複合物的純化方法 | |
| CN112941136B (zh) | 一种重组金黄色葡萄球菌疫苗hi抗原蛋白的纯化方法 | |
| CA3110039A1 (en) | New purification method | |
| KR20050074806A (ko) | 결정형 보툴리늄 독소의 제조방법 | |
| JP2024522931A (ja) | 非毒素タンパク質が除去されたクロストリジウム・ボツリヌス神経毒素タンパク質の精製方法 |